Study of a painful diabetic peripheral neuropathy model induced by streptozotocin: conclusions before investigating non-paralytic botulinum molecules

Painful diabetic peripheral neuropathy (PDPN) is a common complication of diabetes characterized by peripheral nerve dysfunction and debilitating pain symptoms. This article investigates the streptozotocin (STZ)-induced model of PDPN (45 mg/kg i.p.) to evaluate whether it can be further used to study the efficacy of non-paralytic botulinum molecules in pain control. In the study changes in relative weight, glucose levels, and mechanical and temperature sensitivity in the experimental group compared to the control group of rats were assessed. The obtained data indicate the reliability of the model. The results showed a significant decrease in relative weight and alterations in glucose levels in the experimental group, highlighting the metabolic impact of PDPN. Moreover, the rats in the experimental group exhibited heightened mechanical and temperature sensitivity, mirroring the neuropathic pain experienced by patients with PDPN. These findings support the suitability of the STZ-induced PDPN model for preclinical studies investigating non-paralytic botulinum molecules as analgesics. In conclusion, this model provides a valuable platform for future research aimed at understanding the underlying mechanisms and developing effective interventions for PDPN.